Krystal Biotech Expects FY24 Non-GAAP R&D And SG&A Expense Of $150M-$175M
Portfolio Pulse from Benzinga Newsdesk
Krystal Biotech anticipates its non-GAAP research and development (R&D) and selling, general, and administrative (SG&A) expenses for fiscal year 2024 to be between $150 million and $175 million.
February 26, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Krystal Biotech expects its FY24 non-GAAP R&D and SG&A expenses to be between $150M-$175M, indicating significant investment in its operations.
The announcement of projected R&D and SG&A expenses for FY24 by Krystal Biotech suggests a planned increase in operational and development activities. This could be seen as a positive sign of growth and investment in future projects. However, the impact on the stock price in the short term is uncertain, as increased expenses could also raise concerns about profitability among investors.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100